ES2677007T3 - Procedimientos para tratar enfermedades resistentes usando macrólidos que contienen triazol - Google Patents

Procedimientos para tratar enfermedades resistentes usando macrólidos que contienen triazol Download PDF

Info

Publication number
ES2677007T3
ES2677007T3 ES09822827.3T ES09822827T ES2677007T3 ES 2677007 T3 ES2677007 T3 ES 2677007T3 ES 09822827 T ES09822827 T ES 09822827T ES 2677007 T3 ES2677007 T3 ES 2677007T3
Authority
ES
Spain
Prior art keywords
cem
tel
resistant
compound
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09822827.3T
Other languages
English (en)
Spanish (es)
Inventor
David E. Pereira
Prabhavathi B. Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2677007T3 publication Critical patent/ES2677007T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES09822827.3T 2008-10-24 2009-10-24 Procedimientos para tratar enfermedades resistentes usando macrólidos que contienen triazol Active ES2677007T3 (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US108112P 1998-11-12
US10816808P 2008-10-24 2008-10-24
US10811008P 2008-10-24 2008-10-24
US10813708P 2008-10-24 2008-10-24
US10811208P 2008-10-24 2008-10-24
US10813408P 2008-10-24 2008-10-24
US108137P 2008-10-24
US108134P 2008-10-24
US108110P 2008-10-24
US108168P 2008-10-24
US16210909P 2009-03-20 2009-03-20
US162109P 2009-03-20
PCT/US2009/061977 WO2010048600A1 (en) 2008-10-24 2009-10-24 Methods for treating resistant diseases using triazole containing macrolides

Publications (1)

Publication Number Publication Date
ES2677007T3 true ES2677007T3 (es) 2018-07-27

Family

ID=42119711

Family Applications (3)

Application Number Title Priority Date Filing Date
ES09822827.3T Active ES2677007T3 (es) 2008-10-24 2009-10-24 Procedimientos para tratar enfermedades resistentes usando macrólidos que contienen triazol
ES09822828.1T Active ES2565083T3 (es) 2008-10-24 2009-10-24 Biodefensas usando macrólidos que contienen triazol
ES09822826.5T Active ES2676168T3 (es) 2008-10-24 2009-10-24 Procedimientos para tratar enfermedades gastrointestinales

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES09822828.1T Active ES2565083T3 (es) 2008-10-24 2009-10-24 Biodefensas usando macrólidos que contienen triazol
ES09822826.5T Active ES2676168T3 (es) 2008-10-24 2009-10-24 Procedimientos para tratar enfermedades gastrointestinales

Country Status (11)

Country Link
US (7) US8796232B2 (enExample)
EP (4) EP2365747B1 (enExample)
JP (10) JP5602748B2 (enExample)
CN (4) CN105616437A (enExample)
AU (4) AU2009308181B2 (enExample)
DK (1) DK2358379T3 (enExample)
ES (3) ES2677007T3 (enExample)
HK (1) HK1252140A1 (enExample)
HR (1) HRP20160222T1 (enExample)
SI (1) SI2358379T1 (enExample)
WO (3) WO2010048600A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
DK2358379T3 (en) * 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
BR112012023950A2 (pt) * 2010-03-22 2016-07-05 Cempra Pharmaceuticals Inc formas cristalinas de um macrolídeo, e usos dos mesmos
PL2571506T3 (pl) 2010-05-20 2017-10-31 Cempra Pharmaceuticals Inc Sposoby sporządzania makrolidów i ketolidów oraz ich produktów pośrednich
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
WO2014152326A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
BR112015023670A2 (pt) 2013-03-15 2017-07-18 Cempra Pharmaceuticals Inc processo para preparar um composto
BR112015025159A2 (pt) * 2013-04-04 2017-07-18 Harvard College macrolídeos e métodos de sua preparação e uso
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
HK1242920A1 (zh) * 2014-10-08 2018-07-06 哈佛大学的校长及成员们 14-元酮内酯及其制备和使用方法
WO2016154591A1 (en) * 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
CN106554992A (zh) * 2015-09-28 2017-04-05 中国疾病预防控制中心传染病预防控制所 检测耐红霉素弯曲菌的试剂盒
JP2020509086A (ja) * 2017-02-17 2020-03-26 センプラ ファーマシューティカルズ，インコーポレイテッド トリアゾール含有マクロライド及びその眼科的使用
US10706191B2 (en) * 2017-08-31 2020-07-07 Google Llc Systems and methods for generating a geo-level hierarchical Bayesian model
US11145299B2 (en) 2018-04-19 2021-10-12 X Development Llc Managing voice interface devices

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
SE458505B (sv) 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59175414A (ja) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
DE3860503D1 (de) 1987-09-03 1990-10-04 Pliva Pharm & Chem Works 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5968977A (en) * 1995-06-28 1999-10-19 Tokuyama Corporation Ketonitrile derivatives and antibacterial agent and drugs containing the same
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
US5742049A (en) * 1995-12-21 1998-04-21 Bruker-Franzen Analytik Gmbh Method of improving mass resolution in time-of-flight mass spectrometry
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
ATE296831T1 (de) 1996-09-04 2005-06-15 Abbott Lab 6-0-substituierte ketoliden mit antibakteriellen wirkung
EP0944594A4 (en) 1996-12-13 2000-05-03 Lilly Co Eli INHIBITORS OF THE PSA ANTIGEN ENZYMATIC ACTIVITY
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
EP0988308A1 (en) 1997-06-11 2000-03-29 Pfizer Products Inc. 9-oxime erythromycin derivatives
HN1998000074A (es) 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
KR100440553B1 (ko) * 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
EP1137654A1 (en) 1998-12-10 2001-10-04 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
AP2001002222A0 (en) 1999-01-27 2001-09-30 Pfizer Prod Inc Ketolide antibiotics.
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
JP2002542197A (ja) 1999-04-16 2002-12-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ケトライド抗菌剤
AU775637B2 (en) 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO2001010787A1 (en) 1999-08-09 2001-02-15 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
MXPA02008861A (es) 2000-03-15 2003-02-10 Hanmi Pharm Ind Co Ltd Metodo para preparar claritromicina de cristales de forma ii.
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
JP4509553B2 (ja) 2001-07-03 2010-07-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗菌活性を有するｃ１２修飾エリスロマイシンマクロライドおよびケトライド
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
MXPA04008173A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
ES2566761T3 (es) 2002-05-30 2016-04-15 The Scripps Research Institute Ligación de azidas y acetilenos catalizada por cobre
WO2003105775A2 (en) 2002-06-17 2003-12-24 Epigenesis Pharmaceuticals, Inc. Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
JP4790263B2 (ja) 2002-07-08 2011-10-12 グラクソ グループ リミテッド 炎症性の疾患および病態を治療する新規な化合物、組成物および方法
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP3738591A3 (en) * 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
CA2523134A1 (en) 2003-04-25 2004-11-11 Chiron Corporation Pyridyl substituted ketolide antibiotics
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
DK1628989T3 (da) 2003-05-13 2007-10-08 Glaxo Group Ltd Hidtil ukendte, 14- og 15-leddet ring-forbindelser
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
ATE373009T1 (de) 2004-04-28 2007-09-15 Alembic Ltd Verfahren zur vorbereitung von telithromycin
CA2566085A1 (en) 2004-05-06 2005-11-17 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O Ester linked macrolides useful for the treatment of microbial infections
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
WO2006106440A1 (en) 2005-01-14 2006-10-12 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
EP1841437B1 (en) 2005-01-14 2009-04-29 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
EP1835921B1 (en) 2005-01-14 2010-08-18 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CA2614412A1 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
PL1910346T3 (pl) 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
MY148124A (en) 2005-10-31 2013-02-28 Leo Pharma As Preparation of a crystalline antibiotic substance
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
WO2007060518A2 (en) * 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
DOP2006000268A (es) * 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
CN103193840A (zh) 2006-05-01 2013-07-10 大正制药株式会社 大环内酯衍生物
JP2009539866A (ja) 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
DE102006036199B4 (de) * 2006-08-03 2016-01-07 Deere & Company Förderzusammenbau und Presse
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
US20090209547A1 (en) * 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
DK2358379T3 (en) 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
US20110119604A1 (en) 2009-11-19 2011-05-19 Clevest Solutions Inc. System and method for a configurable and extensible allocation and scheduling tool
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
BR112012023950A2 (pt) 2010-03-22 2016-07-05 Cempra Pharmaceuticals Inc formas cristalinas de um macrolídeo, e usos dos mesmos
PL2571506T3 (pl) 2010-05-20 2017-10-31 Cempra Pharmaceuticals Inc Sposoby sporządzania makrolidów i ketolidów oraz ich produktów pośrednich
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
WO2012012257A2 (en) 2010-07-19 2012-01-26 Virginia Commonwealth University BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING Aβ OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE
US20130164351A1 (en) 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
JP5666743B2 (ja) 2011-08-27 2015-02-12 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
BR112015023670A2 (pt) 2013-03-15 2017-07-18 Cempra Pharmaceuticals Inc processo para preparar um composto
BR112015025159A2 (pt) 2013-04-04 2017-07-18 Harvard College macrolídeos e métodos de sua preparação e uso
CA2939076A1 (en) 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
WO2015181723A1 (en) 2014-05-27 2015-12-03 Dipharma Francis S.R.L. Azidoalkylamine salts and their use as intermediates
US20170224664A1 (en) 2014-08-05 2017-08-10 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
US20180044365A1 (en) 2015-03-06 2018-02-15 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides

Also Published As

Publication number Publication date
HK1252140A1 (zh) 2019-05-17
JP2014237710A (ja) 2014-12-18
CN105616437A (zh) 2016-06-01
CN102245195B (zh) 2016-01-13
US20150111845A1 (en) 2015-04-23
JP2021193117A (ja) 2021-12-23
JP2016166224A (ja) 2016-09-15
HRP20160222T1 (hr) 2016-04-08
EP2362727A1 (en) 2011-09-07
AU2016202707A1 (en) 2016-05-19
US20150105339A1 (en) 2015-04-16
EP2358379A4 (en) 2012-05-09
US9072759B2 (en) 2015-07-07
US20110195920A1 (en) 2011-08-11
WO2010048599A1 (en) 2010-04-29
JP2018115177A (ja) 2018-07-26
CN102223794A (zh) 2011-10-19
US20160082028A1 (en) 2016-03-24
CN102245195A (zh) 2011-11-16
EP2362727B1 (en) 2018-04-11
JP5711135B2 (ja) 2015-04-30
US8796232B2 (en) 2014-08-05
JP5922210B2 (ja) 2016-05-24
ES2565083T3 (es) 2016-03-31
EP3031460A1 (en) 2016-06-15
AU2009308181B2 (en) 2015-12-03
AU2009308182A1 (en) 2010-04-29
EP2358379B1 (en) 2015-12-16
AU2009308180A1 (en) 2010-04-29
CN102245022A (zh) 2011-11-16
JP6309995B2 (ja) 2018-04-11
JP2020023544A (ja) 2020-02-13
WO2010048601A1 (en) 2010-04-29
JP2015078203A (ja) 2015-04-23
EP2365747A1 (en) 2011-09-21
JP5602748B2 (ja) 2014-10-08
AU2009308181A1 (en) 2010-04-29
JP2012506871A (ja) 2012-03-22
JP6002185B2 (ja) 2016-10-05
US9439918B2 (en) 2016-09-13
EP2365747B1 (en) 2018-04-11
ES2676168T3 (es) 2018-07-17
JP2012506872A (ja) 2012-03-22
US20110237534A1 (en) 2011-09-29
WO2010048600A1 (en) 2010-04-29
US9901592B2 (en) 2018-02-27
CN107854477A (zh) 2018-03-30
CN102223794B (zh) 2017-12-22
SI2358379T1 (sl) 2016-05-31
EP2362727A4 (en) 2012-05-02
JP2012506870A (ja) 2012-03-22
JP2015061858A (ja) 2015-04-02
US8791080B2 (en) 2014-07-29
JP7171860B2 (ja) 2022-11-15
JP5715569B2 (ja) 2015-05-07
AU2009308182B2 (en) 2016-05-19
US20110201566A1 (en) 2011-08-18
EP2365747A4 (en) 2012-06-13
EP2358379A1 (en) 2011-08-24
JP5908569B2 (ja) 2016-04-26
AU2009308180B2 (en) 2016-01-07
US9669046B2 (en) 2017-06-06
DK2358379T3 (en) 2016-03-07
US20180369262A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
ES2677007T3 (es) Procedimientos para tratar enfermedades resistentes usando macrólidos que contienen triazol
Neu The development of macrolides: clarithromycin in perspective
Hagberg et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia
ES2713954T3 (es) Tratamiento de enfermedades asociadas al uso de antibióticos
Gordon Azithromycin
Müller An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections
Xu et al. Macrolides and ketolides
Van Bambeke Erythromycin
Bryskier Ketolides
CN102245022B (zh) 治疗胃肠病的方法
Bryskiera et al. Group A Streptococcal Pharyngitis?
Uteshev The combination of azithromycin with others. Schemes for taking azithromycin for various STIs. Domestic and foreign analogues
Gaikwad et al. The Review on Azithromycin